Nan Fung Trinity HK Ltd. Makes New $2.83 Million Investment in Exelixis, Inc. $EXEL

Nan Fung Trinity HK Ltd. bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 64,200 shares of the biotechnology company’s stock, valued at approximately $2,830,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Hemington Wealth Management increased its position in Exelixis by 211.3% during the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 522 shares during the last quarter. Byrne Asset Management LLC grew its stake in shares of Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares during the period. Family Legacy Financial Solutions LLC purchased a new stake in shares of Exelixis during the 2nd quarter valued at about $33,000. Costello Asset Management INC bought a new position in shares of Exelixis in the 1st quarter worth approximately $39,000. Finally, Harbour Investments Inc. boosted its holdings in shares of Exelixis by 900.0% in the first quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company’s stock worth $41,000 after buying an additional 990 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Stock Up 3.8%

EXEL opened at $42.97 on Wednesday. The company has a market capitalization of $11.52 billion, a PE ratio of 20.66, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32. The firm has a 50-day simple moving average of $39.16 and a two-hundred day simple moving average of $40.47. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The company had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.47 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on EXEL. Truist Financial reduced their target price on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, July 29th. JMP Securities restated a “market outperform” rating and issued a $50.00 price target on shares of Exelixis in a research report on Tuesday, July 29th. Morgan Stanley lifted their price objective on Exelixis from $44.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Leerink Partnrs upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. Finally, Wells Fargo & Company dropped their price target on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.45.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.